Latest market price
430.36
-1.34-0.31%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -12.89 | Insider Own | 15.01% | Shs Outstand | 23.10M | Perf Week | -0.89% |
| Market Cap | 9.94B | Forward P/E | 74.89 | EPS next Y | 5.75 | Insider Trans | -0.64% | Shs Float | 21.54M | Perf Month | -13.88% |
| Enterprise Value | 9.45B | PEG | — | EPS next Q | -0.83 | Short Float | 10.19% | Perf Quarter | -10.71% | ||
| Income | -325.00M | P/S | 7.75 | EPS this Y | — | Short Ratio | 7.53 | Perf Half Y | -16.23% | ||
| Sales | 1.28B | P/B | 18.98 | EPS next Y | — | ROA | -26.12% | Short Interest | 2.19M | Perf YTD | -26.10% |
| Book/sh | 22.68 | P/C | 11.85 | EPS next 5Y | — | ROE | -56.65% | 52W High | 615.00 -30.02% | Perf Year | 2.08% |
| Cash/sh | 36.31 | P/FCF | — | EPS past 3/5Y | — | ROIC | -37.02% | 52W Low | 399.00 7.86% | Perf 3Y | 248.78% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 91.48% | Volatility | 3.01% 3.58% | Perf 5Y | 449.56% |
| Dividend TTM | — | EV/Sales | 7.37 | EPS Y/Y TTM | — | Oper. Margin | -25.13% | ATR (14) | 16.34 | Perf 10Y | 2696.36% |
| Dividend Ex-Date | — | Quick Ratio | 2.94 | Sales Y/Y TTM | 149.13% | Profit Margin | -25.32% | RSI (14) | 29.50 | Recom | 2.16 |
| Dividend Gr. 3/5Y | — | Current Ratio | 3.20 | EPS Q/Q | -4.74% | SMA20 | -5.90% | Beta | -1.02 | Target Price | 684.80 |
| Payout | 0.00% | Debt/Eq | 0.66 | Sales Q/Q | 70.89% | SMA50 | -13.70% | Rel Volume | 0.94 | Prev Close | 431.70 |
| Employees | 915 | LT Debt/Eq | 0.66 | Earnings | Nov 03 | SMA200 | -13.92% | Avg Volume | 266.96K | Price | 430.36 |
| IPO Date | Feb 06, 2007 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 25.65% 3.46% | Net Debt/EBITDA | — | Volume | 251,449 | Change | -0.31% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-29-26 | Reiterated | B.Riley Financial | Buy | $270 → $670 |
| Oct-14-26 | Reiterated | UBS | Buy | $900 → $735 |
| Sep-24-26 | Resumed | Goldman Sachs | Buy | $571 → $704 |
| Aug-04-26 | Upgrade | Wolfe Research | Peer Perform → Outperform | $579 → $605 |
| Jul-29-26 | Reiterated | Canaccord Genuity | Buy | $578 → $587 |
| Jul-27-26 | Initiated | Wells Fargo | Overweight | $130 → $685 |
| Jun-11-26 | Reiterated | Morgan Stanley | $542 | |
| May-13-26 | Reiterated | Truist Securities | Buy | $640 → $709 |
| May-07-26 | Reiterated | Evercore ISI Group | Outperform | $405 → $649 |
| May-07-26 | Reiterated | Canaccord Genuity | Buy | $420 → $578 |
Latest News· Times ET
Oct-27-26
Oct-27-2611:06AM
08:00AM
Oct-26-26
Oct-20-26
Oct-20-2603:48PM
08:00AM
Oct-15-26
Oct-15-2604:05PM
Oct-12-26
Oct-12-2602:15AM
Oct-06-26
Oct-06-2608:00AM
Sep-24-26
Sep-16-26
Sep-16-2604:05PM
Sep-14-26
Sep-14-2604:45AM
Sep-10-26
Sep-10-2603:17PM
Company
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,283 | 958 | 180 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 109 | 56 | 6 | 0 | — | — | — | — | — | |
| Gross Profit | 1,174 | 902 | 174 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,007 | 814 | 435 | 108 | — | — | — | — | — | |
| Research and Development | 490 | 389 | 237 | 272 | — | — | — | — | — | |
| Other Operating Expense | 0 | -1 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -323 | -300 | -498 | -380 | — | — | — | — | — | |
| Interest Expense | 31 | 22 | 15 | 13 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 28 | 34 | 47 | 20 | — | — | — | — | — | |
| Net Income Before Taxes | -325 | -288 | -466 | -374 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -325 | -288 | -466 | -374 | — | — | — | — | — | |
| Net Income From Continuing Operations | -325 | -288 | -466 | -374 | — | — | — | — | — | |
| Net Income | -325 | -288 | -466 | -374 | — | — | — | — | — | |
| EPS (Recurring) | -12.89 | -12.85 | -21.90 | -19.99 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -12.89 | -12.85 | -21.90 | -19.99 | — | — | — | — | — | |
| EPS (Diluted) | -12.89 | -12.85 | -21.90 | -19.99 | — | — | — | — | — | |
| EBITDA | -292 | -264 | -450 | -360 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 9.73 | 13.37 | 36.00 | — | — | — | — | — | — | |
| Gross Margin | 91.50 | 94.15 | 96.67 | — | — | — | — | — | — | |
| Operating Margin | -25.18 | -31.32 | -276.67 | — | — | — | — | — | — | |
| Net Margin | -25.33 | -30.06 | -258.89 | — | — | — | — | — | — | |
| Shares Outstanding | 29 | 22 | 21 | 19 | — | — | — | — | — | |
| Market Capitalization | 12,480 | 12,811 | 6,480 | 4,396 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Sibold William John | President and CEO | Sep 11 '26 | Sale | 542.39 | 5,221 | 2,831,800 | 197,746 | Sep 11 |
| Sibold William John | President and CEO | Sep 09 '26 | Sale | 535.59 | 6,362 | 3,407,398 | 202,967 | Sep 11 |
| Kelley Shannon T | General Counsel | Aug 17 '26 | Sale | 514.97 | 664 | 341,940 | 11,474 | Aug 20 |
| Sibold William John | President and CEO | Jul 20 '26 | Sale | 547.30 | 2,500 | 1,368,253 | 209,329 | Jul 20 |
| Sibold William John | President and CEO | Jul 17 '26 | Option Exercise | 0.00 | 50,000 | 0 | 211,829 | Jul 20 |
| Soergel David | Chief Medical Officer | Jun 01 '26 | Sale | 495.74 | 1,042 | 516,561 | 10,033 | Jun 01 |
| Levy Richard S | Director | May 22 '26 | Sale | 515.44 | 5,682 | 2,928,716 | 22,015 | May 22 |
| Soergel David | Chief Medical Officer | May 18 '26 | Sale | 515.90 | 844 | 435,420 | 11,075 | May 18 |
| Kelley Shannon T | General Counsel | Mar 06 '26 | Sale | 431.94 | 360 | 155,498 | 12,138 | Mar 06 |
| Dier Mardi | EVP and CFO | Mar 06 '26 | Sale | 430.87 | 1,982 | 853,991 | 12,490 | Mar 06 |
| Sibold William John | President and CEO | Mar 06 '26 | Sale | 431.94 | 1,663 | 718,316 | 161,829 | Mar 06 |
| Huntsman Carole | Chief Commercial Officer | Mar 06 '26 | Sale | 431.94 | 419 | 180,983 | 12,692 | Mar 06 |
| Taub Rebecca | Director | Mar 06 '26 | Sale | 431.94 | 491 | 212,083 | 452,213 | Mar 06 |
| Dier Mardi | EVP and CFO | Mar 02 '26 | Sale | 427.21 | 1,183 | 505,389 | 9,257 | Mar 02 |
| Levy Richard S | Director | Feb 23 '26 | Option Exercise | 7.36 | 2,500 | 18,400 | 27,697 | Feb 24 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.